Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.

Journal of thrombosis and haemostasis : JTH - 1 Sept 2018

Batsuli G, Ito J, Mercer R, Baldwin W H, Cox C, Parker E T, Healey J F, Lollar P, Meeks S L

Abstract excerpt

Essentials Inhibitor formation remains a challenging complication of hemophilia A care. The Bethesda assay is the primary method used for determining bleeding risk and management. Antibodies that block factor VIII binding to von Willebrand factor can increase FVIII clearance. Antibodies that increase clearance contribute to antibody pathogenicity. SUMMARY: Background The development of neutralizing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Factor VIII

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemophilia A

Share to Hemorrhage

Share to Inhibitory Concentration 50

Share to Mice, 129 Strain

Share to von Willebrand Diseases

Share to von Willebrand Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 29981270
DOI: 10.1111/jth.14233
PMCID: PMC6123829

Genes

VWF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.PMID 29981270Read ↗

Predictive significance of anti-FVIII immunoglobulin patterns on bleeding phenotype and outcomes in acquired hemophilia A: Results from the Quebec Reference Center for Inhibitors.Semantic proximity Read ↗

Factor VIII inhibitors.Semantic proximity Read ↗

Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2BSemantic proximity Read ↗

Correlation between factor VIII genotype and inhibitor development in hemophilia A.Semantic proximity Read ↗

A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a non-hemophiliac stateSemantic proximity Read ↗

Classification of the kinetics of factor VIII inhibitors in haemophilia A: plasma dilution studies are more discriminatory than time-course studies.Semantic proximity Read ↗

Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models.Semantic proximity Read ↗

Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.Semantic proximity Read ↗

Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.Semantic proximity Read ↗

von Willebrand factor propeptide to antigen ratio identifies platelet activation and reduced von Willebrand factor survival phenotype in mice.Semantic proximity Read ↗

The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.Semantic proximity Read ↗

Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.